




Supplementary E-Figure 1: Kaplan–Meier plot of fatal AE (ontreatment*)




Supplementary E-Figure 2a: Forest plot of deaths by subgroup for tiotropium Respimat® 2.5 µg versus tiotropium HandiHaler® 18 µg




Supplementary E-Figure 2b: Forest plot of deaths by subgroup for tiotropium Respimat® 5 µg versus tiotropium HandiHaler® 18 µg (vital status analysis).




Supplementary E-Figure 3a: Time to first exacerbation.



Supplementary E-Figure 3b: Time to first moderate-to-severe exacerbation.



Supplementary E-Figure 3c: Time to first severe (hospitalised) exacerbation (ontreatment analysis*).



Supplementary E-Figure 4b: Kaplan–Meier plot of time to fatal MACE by treatment (vital status analysis).